U.S. Markets close in 49 mins
  • S&P 500

    3,619.69
    -99.35 (-2.67%)
     
  • Dow 30

    29,073.99
    -609.75 (-2.05%)
     
  • Nasdaq

    10,656.68
    -394.96 (-3.57%)
     
  • Russell 2000

    1,660.66
    -54.58 (-3.18%)
     
  • Crude Oil

    81.42
    -0.73 (-0.89%)
     
  • Gold

    1,667.30
    -2.70 (-0.16%)
     
  • Silver

    18.73
    -0.15 (-0.82%)
     
  • EUR/USD

    0.9792
    +0.0053 (+0.5484%)
     
  • 10-Yr Bond

    3.7450
    +0.0400 (+1.08%)
     
  • Vix

    32.85
    +2.67 (+8.85%)
     
  • GBP/USD

    1.1051
    +0.0165 (+1.5184%)
     
  • USD/JPY

    144.4260
    +0.3040 (+0.2109%)
     
  • BTC-USD

    19,360.42
    -196.16 (-1.00%)
     
  • CMC Crypto 200

    442.67
    -3.32 (-0.74%)
     
  • FTSE 100

    6,881.59
    -123.80 (-1.77%)
     
  • Nikkei 225

    26,422.05
    +248.07 (+0.95%)
     

This Small-Cap Cancer Stock Has Almost 400% Upside According To This Bullish Analyst

·1 min read
  • Chardan Research initiated coverage of Purple Biotech (NASDAQ: PPBT) with a Buy rating and a price target of $11/share.

  • The analyst is optimistic about the company's two clinical programs:

    • Anti-CEACAM1 monoclonal antibody CM24 for pancreatic ductal adenocarcinoma (PDAC).

    • NT219, the company's insulin receptor substrate 1/2 and STAT3 dual inhibitor small molecule, being developed initially to treat head and neck squamous cell carcinoma (HNSCC).

  • Both programs have shown supportive safety in the clinic and early signs of clinical activity to support further investigation.

  • The company expects multiple data readouts from its programs over the next 12 months that could de-risk its development candidates.

  • Chardan forecasts CM24 and NT219 reaching the U.S. market in 2027 and achieving probability-adjusted global sales in 2030E of $147 million and $61.7 million, respectively.

  • Price Action: PPBT shares are down 5.29% at $2.15 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.